Abstract Library

#4216 Immunohistochemical analysis for galectin-3 and outcomes in medullary thyroid cancer

Introduction: Galectin-3 (Gal-3) is a beta-galactoside involved in multiple biological and pathological processes including growth and differentiation, cellular adhesion and transformation, and metastatic potential.

Conference:

Presenting Author: Raia S

Authors: Raia S, Chiloiro S, Giampietro A, Lugli F, Maratta M,

Keywords: Thyroid, MTC, Galectine3,

#3818 Somatostatin analogues or active surveillance in sporadic non-functioning pancreatic neuroendocrine tumors

Introduction: Non-functioning (NF), sporadic, G1-G2 pancreatic neuroendocrine tumors (PanNETs) usually display an indolent course. Surgery is the first-choice treatment for localized tumors >2 cm. Unresectable or metastatic PanNETs expressing somatostatin receptors (SSTRs) are treated with somatostatin analogues (SSAs). The PROMID and the CLARINET studies proved the SSA antiproliferative effect in advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The standard treatment for patients with PanNETs ≤2cm is active surveillance (AS). Yet no evidence of the value of SSA treatment exist in such patient population.

Conference:

Presenting Author: Maratta M

Authors: Maratta M, Chiloiro S, Raia S, Maiorano B, Rossi E,

Keywords: PanNET, somatostatin analogues, efficacy, surveillance, medical treatment,

#3632 Medullary thyroid carcinoma and somatostatin analogues, a possible therapeutic choice in asymptomatic and slow radiological progression metastatic recurrent disease after surgery – Case report of a 22-years long term survival patient

Introduction: Medullary thyroid carcinoma (MTC) is a well-differentiated neuroendocrine tumor of the thyroid and accounts for 1%-2% of thyroid cancers in the United States. MTCs present with locoregional metastasis in 50% of patients and distant metastasis in 10%-15% at diagnosis. Treatment options for recurrent or progressive disease according to RECIST 1.1 criteria, are limited. Tyrosine kinase-inhibitors (TKI) are preferred as first-line systemic therapy. Although somatostatin analogues (SSA) may play a role in MTC, limited evidence is available.

Conference:

Presenting Author: Raia S

Authors: Raia S, Chiloiro S, Maratta M, Giampietro A, de Marinis L,

Keywords: medullary thyroid carcinoma (MTC), somatostatin analogues, survival,

#3266 The psychological impact of COVID-19 pandemic in patients with NETs: Between resilience and vulnerability

Introduction: The COVID-19 pandemic has dramatically changed lifestyles and quality of life (QoL) of the global population. Little is known regarding the psychological impact of COVID-19 in patients with gastroenteropancreatic (GEP) or bronchopulmonary (BP) NETs.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Lauricella E

Authors: Lauricella E, Cives M, Bracigliano A, Lamia S, Felici V,

Keywords: covid-19, net, depression, anxiety, quality of life,

#3048 Somatostatin Analogs or Active Surveillance in Sporadic Non-Functioning Pancreatic Neuroendocrine Tumors

Introduction: Non-functioning (NF), sporadic pancreatic neuroendocrine tumors (pNETs) have usually an indolent behavior, but sometimes show an unpredictable aggressiveness. Surgery is the first-choice for localized tumors >2 cm. Unresectable or metastatic lesions expressing somatostatin receptors (SSTRs) are treated with Somatostatin analogs (SSAs). No evidence of SSAs efficacy exists in tumors ≤2 cm, for which active surveillance has been proposed.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Schinzari G, Maiorano B, Rossi E, Bianchi A, Chiloiro S,

Keywords: pNET, non-functioning, sporadic, somatostatin analogs, surveillance,